| Literature DB >> 26174807 |
Ida Iren Eriksen1, Hans Olav Melberg.
Abstract
BACKGROUND: To examine the impact of introducing an electronic prescription system with no copayments on the number of prescriptions, the size of prescriptions, and the number of visits and phone calls to primary physicians.Entities:
Year: 2015 PMID: 26174807 PMCID: PMC4502047 DOI: 10.1186/s13561-015-0056-4
Source DB: PubMed Journal: Health Econ Rev ISSN: 2191-1991
Total reimbursement rates to physicians for providing paper based vs. electronic prescriptions and the amount paid by the state vs. the patient
| Paper based prescriptions (NOK) | Electronic prescriptions (NOK) | |||||
|---|---|---|---|---|---|---|
| Total | State | Patient | Total | State | Patient | |
| 2008-2009 | 50 | 15 | 35 | |||
| 2009-2010 | 45 | 5 | 40 | |||
| 2010- 2011 | 50 | 5 | 45 | |||
| 2011-2012 | 50 | 5 | 45 | 50 | 50 | 0 |
| 2012-2013 | 54 | 9 | 45 | 54 | 54 | 0 |
| 2013-2014 | 55 | 9 | 46 | 55 | 55 | 0 |
Fig. 1Percentage of all municipalities with electronic prescription systems
Fig. 2Monthly numbers of reimbursed claims at the national level (total, regular paper based and electronic prescriptions)
Fig. 3Number of reimbursement claims per capita in counties who introduced electronic prescriptions in 2012 (fully or partially) and counties that did not
Results from the fixed effect regression model estimating how the electronic system and other factors affected the number prescriptions (per capita per month in municipalities, N = 21 419)
| Threshold: 1 | Threshold: 50 | Threshold: 100 | ||||
|---|---|---|---|---|---|---|
| E-prescription (Dummy) | 0,0060 | *** | 0,0049 | *** | 0,0046 | *** |
| February | −0,0065 | *** | −0,0064 | *** | −0,0064 | *** |
| March | 0,0028 | *** | 0,0020 | *** | 0,0030 | *** |
| April | −0,0035 | ** | −0,0039 | *** | −0,0040 | *** |
| May | 0,0013 | ** | 0,0010 | * | 0,0008 | |
| June | 0,0039 | *** | 0,0026 | *** | 0,0036 | *** |
| July | −0,0089 | *** | −0,0090 | *** | −0,0090 | *** |
| August | −0,0022 | *** | −0,0023 | *** | −0,0023 | *** |
| September | −0,0030 | *** | −0,0030 | *** | −0,0030 | *** |
| October | −0,0009 | * | −0,0010 | * | −0,0009 | * |
| November | 0,0018 | ** | 0,0018 | ** | 0,0018 | *** |
| December | 0,0003 | 0,0005 | 0,0005 | |||
| Constant term | 0,0751 | *** | 0,0758 | *** | 0,0760 | *** |
*** Statistically significant at the 1 % level (**; 5 %, *; 10 %). The different thresholds represent how many times e-prescriptions have to be used in a month before the system is considered implemented in the municipality. Robust estimation of standard errors was used since the Modified Wald test indicated presence of groupwise heteroscadasticity
Fig. 4Pharmacautial market, Defined Daily Dose per capita from 2006 to 2012
Fixed effect regression of the per capita monthly number of daytime phone consultations with patients and daytime office consultations
| Daytime phone consultations | Daytime office consultations | |||||
|---|---|---|---|---|---|---|
| Variable | Coefficient | Standard Error | Coefficient | Standard Error | ||
| E-prescription | 0,0028 | *** | 0,0009 | −0,0005 | 0,0013 | |
| February | −0,0058 | *** | 0,0002 | −0,0255 | *** | 0,0009 |
| March | −0,0008 | ** | 0,0004 | −0,0058 | *** | 0,0008 |
| April | −0,0127 | *** | 0,0005 | −0,0638 | *** | 0,0028 |
| May | −0,0064 | *** | 0,0005 | −0,0194 | *** | 0,0010 |
| June | −0,0053 | *** | 0,0005 | −0,0154 | *** | 0,0011 |
| July | −0,0266 | *** | 0,0008 | −0,0781 | *** | 0,0040 |
| August | −0,0140 | *** | 0,0007 | −0,0287 | *** | 0,0017 |
| September | −0,0066 | *** | 0,0007 | −0,0014 | 0,0020 | |
| October | −0,0031 | *** | 0,0062 | 0,0029 | * | 0,0016 |
| November | 0,0017 | *** | 0,0000 | 0,0139 | *** | 0,0016 |
| December | −0,0128 | *** | 0,0006 | −0,0308 | *** | 0,0020 |
| Constant term | 0,0773 | *** | 0,0004 | 0,2532 | *** | 0,0011 |
*** Statistically significant at the 1 % level (**; 5 %, *; 10 %). Robust estimation of standard errors was used since the Modified Wald test indicated presence of groupwise heteroscedasticity
Key results from regressions testing whether the effect differed depending on the time of intervention, the length of time after the intervention, and whether annual dummies would eliminate the effect (N = 21 419)
| Time of intervention adopters | Time after intervention | Annual dummies | ||||
|---|---|---|---|---|---|---|
| E-prescription (Dummy) | 0,0047 | *** | 0,0008 | * | 0,0008 ( (0,0004) | ** |
| Dummy for late adopters | 0,0009 | |||||
| Linearly increasing effect | 0.0006 | *** | ||||
| Dummy for 2010 | −0,0007 | ** | ||||
| Dummy for 2011 | 0,0006 | * | ||||
| Dummy for 2012 | 0,0037 | *** | ||||
| Dummy for 2013 | 0,0087 | *** | ||||
*** Statistically significant at the 1 % level (**; 5 %, *; 10 %)
Fig. 5Distribution of coefficients for effect of electronic precriptions in one thousand regression simulations assuming random dates for the intervention (observed result with true dates marked in red)